UniQure’s market value plunged after FDA Commissioner Marty Makary’s public defense of the agency’s review approach and comments suggesting some recent rare‑disease approvals were pressured. Investors interpreted the remarks as potentially signaling tougher FDA scrutiny for certain gene‑therapy delivery routes, prompting a more than 30% share drop and sharp market reaction. Analysts cautioned Makary may not have been targeting UniQure specifically, but the company’s AMT‑130 program has faced heightened attention. The episode underscores how regulatory rhetoric can move markets for companies reliant on high‑risk, high‑reward gene therapies and highlights investor sensitivity to approval headwinds in the rare disease space. Coverage combined CNBC reporting and market analysis.